Berdazimer - Generic Drug Details
✉ Email this page to a colleague
US Patents and Regulatory Information for Berdazimer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | 9,289,442 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | 9,526,738 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | 9,855,211 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | 8,282,967 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | 11,285,098 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | 11,723,858 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
